Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuideAI HealthFRA:ZN0 +4.54%16 EV-to-EBITDA is -54.24 as of Sep. 10, 2026. GuruFocus rates FRA:ZN0 with a GF Score™ of 16/100. Among 515 Healthcare Providers & Services companies, GuideAI Health ranks worse than 194174.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GuideAI Health's enterprise value is €43.83 Mil.
GuideAI Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.81 Mil. Therefore, GuideAI Health's EV-to-EBITDA for today is -54.24.
The historical rank and industry rank for GuideAI Health's EV-to-EBITDA or its related term are showing as below:
FRA:ZN0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -63.48 Med: 0 Max: 0
Current: -63.48
FRA:ZN0's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Healthcare Providers & Services industry
Industry Median: 10.57
vs FRA:ZN0: -63.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GuideAI Health's PE Ratio (TTM) for today is calculated as:
GuideAI Health's share price for today is €0.668.
GuideAI Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.016.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for GuideAI Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuideAI Health EV-to-EBITDA Chart
GuideAI Health Annual Data
Trend
Jun23
Jun24
Jun25
EV-to-EBITDA
0.00
0.00
0.00
GuideAI Health Quarterly Data
Jun23
Jun24
Mar25
Jun25
Mar26
EV-to-EBITDA
0.00
0.00
0.00
0.00
0.00
FRA:ZN0 vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, GuideAI Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GuideAI Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GuideAI Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GuideAI Health's EV-to-EBITDA falls into.
GuideAI Health's current Enterprise Value is €43.83 Mil.
GuideAI Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuideAI Health (FRA:ZN0) has a EV-to-EBITDA of -54.24 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GuideAI Health. According to the industry distribution chart, GuideAI Health ranks #999999 out of 515 companies in the Healthcare Providers & Services industry.
Is GuideAI Health's EV-to-EBITDA too high?
GuideAI Health's current EV-to-EBITDA is -54.24. Based on the distribution chart, GuideAI Health ranks #999999 out of 515 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, GuideAI Health has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does GuideAI Health's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, GuideAI Health ranks #999999 out of 515 companies for EV-to-EBITDA. This places GuideAI Health in the lower half of its industry. The industry median EV-to-EBITDA is 10.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.57, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GuideAI Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GuideAI Health's current EV-to-EBITDA is -54.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GuideAI Health stock overvalued right now?
GuideAI Health (FRA:ZN0) has a current EV-to-EBITDA of -54.24. The current EV-to-EBITDA is -54.24. GuideAI Health's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GuideAI Health (FRA:ZN0), the current EV-to-EBITDA is -54.24 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GuideAI Health Corp is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease and other vascular conditions that are frequently missed or under-reported, generating structured, actionable reports for radiologists and treating clinicians. By surfacing disease earlier and matching findings to appropriate treatment pathways, it aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care. Its Platform Capabilities are AI-powered vascular imaging, Early detection of disease, subtle patterns and risk signals, Structured, consistent AI-generated, and Others.
16GF Score
Get the complete analysis for FRA:ZN0
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZN0 has been successfully added to your 
